GlaxoSmithKline Biologicals, Global Vaccine Policy and Public Health Partnerships, Parc de la Noire Epine 20, B-1300 Wavre, Belgium.
Vaccine. 2009 Dec 30;27 Suppl 6:G3-8. doi: 10.1016/j.vaccine.2009.10.014.
Advances in biotechnology and immunology are yielding exciting progress in the development of new biologics and vaccines. Yet in both the developed and developing world, we see a backlog of new vaccines that are licensed but not yet used, an "innovation pile-up", which may prevent individuals and societies from benefiting from protection against preventable infectious diseases. What is the "need for new vaccines"? Reviewing the vaccines environment and the place of vaccination in public health, we present our business model that we use to sustainably deliver the benefits of vaccination and review potential solutions to accelerating the introduction and adoption of under-utilised and future vaccines.
生物技术和免疫学的进步正在为新生物制剂和疫苗的开发带来令人兴奋的进展。然而，在发达国家和发展中国家，我们都看到了一大批已获得许可但尚未使用的新疫苗，这是一种“创新堆积”，可能会使个人和社会无法从预防传染病的保护中受益。那么，什么是“新疫苗的需求”呢？我们在审查疫苗环境和疫苗在公共卫生中的作用的同时，提出了我们用以可持续地提供疫苗效益的商业模式，并探讨了加速利用和采用未充分利用的现有疫苗和未来疫苗的潜在解决方案。
